Clinical Trial

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by…

8 months ago

Phantom Neuro Secures $19M Series A Funding Led by Ottobock to Advance Neural Interface Technology for Prosthetics and Robotics

Investment will accelerate clinical trials and commercialization of Phantom X, with Ottobock joining Phantom Neuro's Board of Directors AUSTIN, Texas,…

9 months ago

Cadwell Makes a Strategic Investment in Seer Medical to Expand Home-Based Epilepsy Diagnostics

KENNEWICK, Wash., April 15, 2025 /PRNewswire/ -- Cadwell Industries, Inc., a global leader in neurodiagnostic, neuromonitoring, and sleep solutions, today…

9 months ago

Volta Medical Announces Presentations at Heart Rhythm Society 2025 in San Diego, CA, USA

Co-founder Dr. Clément Bars to present on additional TAILORED-AF clinical trial findingsDr. John Hummel to present the initial outcomes of…

9 months ago

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ -- Leap Therapeutics,…

9 months ago

Red Light Holland’s Partner FDA-Compliant and DEA-Registered Irvine Labs Receives 2025 Psilocybin DEA Quotas, Including Import Quota

The companies are now moving forward with the import permit application process.Following expected approval of the import permit, Red Light…

9 months ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company")…

9 months ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with…

9 months ago

NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1×1 Meetings on Thursday, April 24, 2025

CARMEL, Ind., April 15, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology…

9 months ago